败血症诱导的ALI/ARDS超出了支持性护理:分子机制和尖端疗法
Muhammad Qasim Barkat1, Qiao Li2, Majid Manzoor1
1Institute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China; Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences at Ningbo University, Ningbo, China.
International immunopharmacology
|September 16, 2025
概括
败血症引起的急性肺损伤/急性呼吸困扰综合征 (ALI/ARDS) 由于复杂的机制,缺乏有效的治疗方法. 创新疗法对于改善这种关键病情的结果至关重要.
科学领域:
- 肺部医学 肺部医学
- 临界护理医学 临界护理医学
- 分子生物学分子生物学
背景情况:
- 败血症诱导的ALI/ARDS涉及复杂的分子和细胞途径,包括内皮功能障碍,免疫失调,表观遗传改变和氧化应激.
- 这些机制损害了内皮的完整性,导致细胞死亡,肺部损伤恶化和呼吸衰竭.
- 与COVID-19相关的ARDS与败血症诱导的ALI/ARDS有相似之处,其特点是严重的免疫失调,细胞因子风暴和微血栓.
研究的目的:
- 审查导致败血症的ALI/ARDS背后的分子和细胞机制.
- 检查关键的细胞信号通路,涉及到败血症诱导的ALI/ARDS.
- 讨论有关COVID-19相关的ALI/ARDS的临床见解,并探索当前和新兴的治疗策略.
主要方法:
- 文献综述侧重于毒诱导的ALI/ARDS的分子和细胞机制.
- 参与败血症引起的肺损伤的信号通路的分析.
- 关于COVID-19相关的ALI/ARDS和治疗选择的临床数据的综合.
主要成果:
- 败血症诱导的ALI/ARDS病原体是多因素的,涉及内皮功能障碍和免疫反应.
- 目前针对败血症诱导的ALI/ARDS的治疗方法主要是支持性,缺乏有效的药理选择.
- 与COVID-19相关的ARDS带来了独特的挑战,包括严重的炎症和微血管血栓形成.
结论:
- 败血症引起的ALI/ARDS仍然是一个重大的临床挑战,没有特定的药理疗法,通常被称为重症监护的"百慕大三角".
- 迫切需要新的治疗策略来解决因败血症引起的ALI/ARDS复杂的病理生理学.
- 对潜在机制的进一步研究对于开发有效的治疗方法和提高患者存活率至关重要.
相关概念视频
Acute Respiratory Failure-V
466
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
466
Pneumonia IV: Management
756
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
756
Heart Failure VI: Adjunct Therapies
261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261
Gene Regulation in Microbial Communities: Quorum Sensing
533
Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
533
Pleural Effusion II: Symptoms and Management
660
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
660
Cardiopulmonary Resuscitation IV: Pharmacological Management
675
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
675


